Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Oct;74(7):1023–1029. doi: 10.1038/bjc.1996.484

Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo.

M H Vingerhoeds 1, P A Steerenberg 1, J J Hendriks 1, L C Dekker 1, Q G Van Hoesel 1, D J Crommelin 1, G Storm 1
PMCID: PMC2077130  PMID: 8855969

Abstract

This paper deals with the utility of immunoliposomes for the delivery of doxorubicin (DXR) to human ovarian carcinoma cells in vitro and in vivo. We aimed to investigate whether immunoliposome-mediated targeting of DXR to ovarian cancer cells translates in an enhanced anti-tumour effect compared with that of non-targeted DXR liposomes (lacking the specific antibody). Target cell binding and anti-tumour activity of DXR immunoliposomes were studied in vitro and in vivo (xenograft model of ovarian carcinoma). In vitro we observed that target cell binding and cell growth inhibition of DXR immunoliposomes is superior to that of non-targeted DXR-liposomes. However, in vivo, despite the efficient target cell binding and good anti-tumour response of DXR-immunoliposomes, no difference in anti-tumour effect, compared with non-targeted DXR-liposomes, could be determined. The results indicate that premature DXR leakage from immunoliposomes occurring before the actual target cell binding and subsequent DXR association with the tumour cells, explains why no significant differences in anti-tumour activity between DXR-immunoliposomes and non-targeted DXR-liposomes were observed in vivo.

Full text

PDF
1023

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boerman O., Massuger L., Makkink K., Thomas C., Kenemans P., Poels L. Comparative in vitro binding characteristics and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies. Anticancer Res. 1990 Sep-Oct;10(5A):1289–1295. [PubMed] [Google Scholar]
  2. Delgado G., Potkul R. K., Treat J. A., Lewandowski G. S., Barter J. F., Forst D., Rahman A. A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer. Am J Obstet Gynecol. 1989 Apr;160(4):812–819. doi: 10.1016/0002-9378(89)90296-2. [DOI] [PubMed] [Google Scholar]
  3. Forssen E. A., Tökès Z. A. Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proc Natl Acad Sci U S A. 1981 Mar;78(3):1873–1877. doi: 10.1073/pnas.78.3.1873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hamilton T. C., Young R. C., Louie K. G., Behrens B. C., McKoy W. M., Grotzinger K. R., Ozols R. F. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res. 1984 Nov;44(11):5286–5290. [PubMed] [Google Scholar]
  5. Hamilton T. C., Young R. C., McKoy W. M., Grotzinger K. R., Green J. A., Chu E. W., Whang-Peng J., Rogan A. M., Green W. R., Ozols R. F. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 1983 Nov;43(11):5379–5389. [PubMed] [Google Scholar]
  6. Haran G., Cohen R., Bar L. K., Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta. 1993 Sep 19;1151(2):201–215. doi: 10.1016/0005-2736(93)90105-9. [DOI] [PubMed] [Google Scholar]
  7. Markman M., Hakes T., Reichman B., Hoskins W., Rubin S., Jones W., Almadones L., Lewis J. L., Jr Intraperitoneal therapy in the management of ovarian carcinoma. Yale J Biol Med. 1989 Jul-Aug;62(4):393–403. [PMC free article] [PubMed] [Google Scholar]
  8. Markman M. Intraperitoneal chemotherapy. Semin Oncol. 1991 Jun;18(3):248–254. [PubMed] [Google Scholar]
  9. Martin F. J., Papahadjopoulos D. Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. J Biol Chem. 1982 Jan 10;257(1):286–288. [PubMed] [Google Scholar]
  10. Maruyama K., Unezaki S., Takahashi N., Iwatsuru M. Enhanced delivery of doxorubicin to tumor by long-circulating thermosensitive liposomes and local hyperthermia. Biochim Biophys Acta. 1993 Jul 4;1149(2):209–216. doi: 10.1016/0005-2736(93)90203-c. [DOI] [PubMed] [Google Scholar]
  11. Massuger L. F., Kenemans P., Claessens R. A., Verheijen R. H., Corstens F. H. Detection and localization of ovarian cancer with radiolabeled monoclonal antibodies. Eur J Obstet Gynecol Reprod Biol. 1991 Aug 20;41(1):47–63. doi: 10.1016/0028-2243(91)90319-g. [DOI] [PubMed] [Google Scholar]
  12. Moseley K. R., Battaile A., Knapp R. C., Haisma H. J. Localization of radiolabelled F(ab')2 fragments of monoclonal antibodies in nude mice bearing intraperitoneally growing human ovarian cancer xenografts. Int J Cancer. 1988 Sep 15;42(3):368–372. doi: 10.1002/ijc.2910420311. [DOI] [PubMed] [Google Scholar]
  13. Nässander U. K., Steerenberg P. A., De Jong W. H., Van Overveld W. O., Te Boekhorst C. M., Poels L. G., Jap P. H., Storm G. Design of immunoliposomes directed against human ovarian carcinoma. Biochim Biophys Acta. 1995 Apr 12;1235(1):126–139. doi: 10.1016/0005-2736(94)00300-e. [DOI] [PubMed] [Google Scholar]
  14. Nässander U. K., Steerenberg P. A., Poppe H., Storm G., Poels L. G., De Jong W. H., Crommelin D. J. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice. Cancer Res. 1992 Feb 1;52(3):646–653. [PubMed] [Google Scholar]
  15. Ozols R. F., Young R. C., Speyer J. L., Sugarbaker P. H., Greene R., Jenkins J., Myers C. E. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res. 1982 Oct;42(10):4265–4269. [PubMed] [Google Scholar]
  16. Poels L. G., Peters D., van Megen Y., Vooijs G. P., Verheyen R. N., Willemen A., van Niekerk C. C., Jap P. H., Mungyer G., Kenemans P. Monoclonal antibody against human ovarian tumor-associated antigens. J Natl Cancer Inst. 1986 May;76(5):781–791. [PubMed] [Google Scholar]
  17. Pool G. L., French M. E., Edwards R. A., Huang L., Lumb R. H. Use of radiolabeled hexadecyl cholesteryl ether as a liposome marker. Lipids. 1982 Jun;17(6):448–452. doi: 10.1007/BF02535225. [DOI] [PubMed] [Google Scholar]
  18. Rubinstein L. V., Shoemaker R. H., Paull K. D., Simon R. M., Tosini S., Skehan P., Scudiero D. A., Monks A., Boyd M. R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst. 1990 Jul 4;82(13):1113–1118. doi: 10.1093/jnci/82.13.1113. [DOI] [PubMed] [Google Scholar]
  19. Rygaard J., Friis C. W. The husbandry of mice with congenital absence of the thymus (nude mice). Z Versuchstierkd. 1974;16(1):1–10. [PubMed] [Google Scholar]
  20. Singh M., Ghose T., Mezei M., Belitsky P. Inhibition of human renal cancer by monoclonal antibody targeted methotrexate-containing liposomes in an ascites tumor model. Cancer Lett. 1991 Feb;56(2):97–102. doi: 10.1016/0304-3835(91)90082-s. [DOI] [PubMed] [Google Scholar]
  21. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4;82(13):1107–1112. doi: 10.1093/jnci/82.13.1107. [DOI] [PubMed] [Google Scholar]
  22. Stein Y., Halperin G., Stein O. Biological stability of [3H]cholesteryl oleyl ether in cultured fibroblasts and intact rat. FEBS Lett. 1980 Feb 25;111(1):104–106. doi: 10.1016/0014-5793(80)80771-x. [DOI] [PubMed] [Google Scholar]
  23. Storm G., van Bloois L., Brouwer M., Crommelin D. J. The interaction of cytostatic drugs with adsorbents in aqueous media. The potential implications for liposome preparation. Biochim Biophys Acta. 1985 Sep 10;818(3):343–351. doi: 10.1016/0005-2736(85)90008-2. [DOI] [PubMed] [Google Scholar]
  24. Straubinger R. M., Lopez N. G., Debs R. J., Hong K., Papahadjopoulos D. Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes. Cancer Res. 1988 Sep 15;48(18):5237–5245. [PubMed] [Google Scholar]
  25. WISH L., FURTH J., STOREY R. H. Direct determinations of plasma, cell, and organ-blood volumes in normal and hypervolemic mice. Proc Soc Exp Biol Med. 1950 Jul;74(3):644–648. doi: 10.3181/00379727-74-18003. [DOI] [PubMed] [Google Scholar]
  26. Wessel D., Flügge U. I. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem. 1984 Apr;138(1):141–143. doi: 10.1016/0003-2697(84)90782-6. [DOI] [PubMed] [Google Scholar]
  27. Yatvin M. B., Weinstein J. N., Dennis W. H., Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science. 1978 Dec 22;202(4374):1290–1293. doi: 10.1126/science.364652. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES